István Szombati

1.3k total citations · 1 hit paper
13 papers, 892 citations indexed

About

István Szombati is a scholar working on Rheumatology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, István Szombati has authored 13 papers receiving a total of 892 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Rheumatology, 6 papers in Genetics and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in István Szombati's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (4 papers), Vasculitis and related conditions (4 papers) and Otitis Media and Relapsing Polychondritis (3 papers). István Szombati is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (4 papers), Vasculitis and related conditions (4 papers) and Otitis Media and Relapsing Polychondritis (3 papers). István Szombati collaborates with scholars based in Germany, United Kingdom and Belgium. István Szombati's co-authors include Matthias Schaier, Thomas J. Schall, Pirow Bekker, Mårten Segelmark, Michel Jadoul, Annette Bruchfeld, Michael Venning, David Jayne, Lorraine Harper and Antonia Potarca and has published in prestigious journals such as Journal of the American Society of Nephrology, Annals of the Rheumatic Diseases and Osteoarthritis and Cartilage.

In The Last Decade

István Szombati

13 papers receiving 863 citations

Hit Papers

Randomized Trial of C5a R... 2017 2026 2020 2023 2017 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
    2017 420 citations David Jayne, Annette Bruchfeld et al. Journal of the American Society of Nephrology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
István Szombati Germany 6 317 296 289 151 138 13 892
Susan W. Burriss United States 10 623 2.0× 479 1.6× 68 0.2× 27 0.2× 199 1.4× 11 1.1k
Mihaela Mates Israel 11 425 1.3× 82 0.3× 514 1.8× 171 1.1× 64 0.5× 16 764
George B.M. Lindop United Kingdom 21 110 0.3× 113 0.4× 339 1.2× 27 0.2× 173 1.3× 77 1.3k
Yachiyo Kuwatsuka Japan 17 34 0.1× 181 0.6× 54 0.2× 112 0.7× 25 0.2× 74 941
Sarah E. Panzer United States 17 77 0.2× 196 0.7× 117 0.4× 61 0.4× 256 1.9× 46 721
Bianca Marasini Italy 20 289 0.9× 218 0.7× 107 0.4× 337 2.2× 11 0.1× 56 1.2k
Rüdiger Waldherr Germany 9 120 0.4× 116 0.4× 343 1.2× 89 0.6× 230 1.7× 9 632
Ruvie Martin Switzerland 15 1.3k 4.2× 1.0k 3.4× 285 1.0× 29 0.2× 23 0.2× 29 2.1k
Paula I. Burgos Chile 15 511 1.6× 413 1.4× 50 0.2× 26 0.2× 45 0.3× 33 893
Akiko Mii Japan 18 78 0.2× 213 0.7× 147 0.5× 59 0.4× 407 2.9× 57 865

Countries citing papers authored by István Szombati

Since Specialization
Citations

This map shows the geographic impact of István Szombati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by István Szombati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites István Szombati more than expected).

Fields of papers citing papers by István Szombati

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by István Szombati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by István Szombati. The network helps show where István Szombati may publish in the future.

Co-authorship network of co-authors of István Szombati

This figure shows the co-authorship network connecting the top 25 collaborators of István Szombati. A scholar is included among the top collaborators of István Szombati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with István Szombati. István Szombati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Jayne, David, Annette Bruchfeld, Lorraine Harper, et al.. (2017). Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. Journal of the American Society of Nephrology. 28(9). 2756–2767. 420 indexed citations breakdown →
2.
Alten, Rieke, René Westhovens, Arthur Kavanaugh, et al.. (2017). THU0173 Long term safety and efficacy of filgotinib in a phase 2B open label extension study in patients with rheumatoid arthritis: results up to 144 weeks. Annals of the Rheumatic Diseases. 76. 267–267. 3 indexed citations
3.
Jayne, David, Annette Bruchfeld, Lorraine Harper, et al.. (2016). MO039SUCCESSFUL STEROID REPLACEMENT IN ANCA-ASSOCIATED VASCULITIS WITH C5A RECEPTOR INHIBITOR CCX168 IN PHASE 2 RANDOMISED TRIAL (CLEAR). Nephrology Dialysis Transplantation. 31(suppl_1). i45–i45. 2 indexed citations
4.
Smolen, Josef S, Serghei Popa, István Szombati, et al.. (2015). OP0185 Significant Clinical Improvement and Reduction of Severe Flares Following Administration of an IL-6 Monoclonal Antibody in Systemic Lupus Erythematosus (SLE) Subjects with High Disease Activity. Annals of the Rheumatic Diseases. 74. 141–142. 2 indexed citations
5.
Jayne, David, Annette Bruchfeld, Matthias Schaier, et al.. (2014). Phase 2 randomised trial of oral C5A receptor antagonist CCX168 in ANCA-associated renal vasculitis. Nephrology Dialysis Transplantation. 29. 4 indexed citations
6.
Jayne, David, Annette Bruchfeld, Matthias Schaier, et al.. (2014). OP0227 Oral C5a Receptor Antagonist CCX168 Phase 2 Clinical TRIAL in Anca-Associated Renal Vasculitis. Annals of the Rheumatic Diseases. 73. 148–148. 12 indexed citations
7.
Buttgereit, Frank, John Kirwan, Jacek Szechiński, et al.. (2013). Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Annals of the Rheumatic Diseases. 72(2). 204–210. 131 indexed citations
8.
Bruchfeld, Annette, Matthias Schaier, Michel Jadoul, et al.. (2013). C5aR inhibitor on leukocytes exploratory ANCA associated renal vasculitis (CLEAR) clinical trial with orally administered CCX168. La Presse Médicale. 42(4). 768–769. 2 indexed citations
9.
Bruchfeld, Annette, Matthias Schaier, Lorraine Harper, et al.. (2013). Phase 2 clinical trial of CCX168, an orally administered C5aR antagonist, in patients with ANCA-associated renal vasculitis (CLEAR). Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)). 1 indexed citations
10.
Burmester, Gerd R, Michael E. Weinblatt, Iain B. McInnes, et al.. (2012). Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Annals of the Rheumatic Diseases. 72(9). 1445–1452. 132 indexed citations
11.
12.
Szombati, István, et al.. (2009). 324 CG100649, A TISSUE-SPECIFIC DUAL INHIBITOR OF COX-2 AND CARBONIC ANHYDRASE: PHASE 2A CLINICAL TRIAL IN HIP & KNEE OSTEOARTHRITIS. Osteoarthritis and Cartilage. 17. S173–S173. 5 indexed citations
13.
Leyendecker, Petra, Winfried Meißner, Michael Hopp, et al.. (2008). Analgesic Efficacy and Safety of Oxycodone in Combination With Naloxone as Prolonged Release Tablets in Patients With Moderate to Severe Chronic Pain. Journal of Pain. 9(12). 1144–1154. 162 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan W. Burriss Breakdown of academic impact, for papers by Mihaela Mates Breakdown of academic impact, for papers by George B.M. Lindop Breakdown of academic impact, for papers by Yachiyo Kuwatsuka Breakdown of academic impact, for papers by Sarah E. Panzer Breakdown of academic impact, for papers by Bianca Marasini Breakdown of academic impact, for papers by Rüdiger Waldherr Breakdown of academic impact, for papers by Ruvie Martin Breakdown of academic impact, for papers by Paula I. Burgos Breakdown of academic impact, for papers by Akiko Mii
Rankless by CCL
2026